News

As a result of the closing, the company will issue 5.77 million shares of common stock and warrants to acquire 5.77 million shares of common stock at an

As a result of this regulatory progress, the company and Nordic Biotech Venture Fund II (Nordic) have amended their joint venture agreement for the development and commercialization of

The company presented the data in a subset of 26 patients with high-risk myelodysplastic syndromes (MDS) by French-American-British Group criteria. The median age of the patients in the

Approximately 17 subjects have received at least one dose of XL228, of whom 16 had completed cycle 1. The trial is evaluating a treatment cycle consisting of four

The Phase II data indicated that Arikace, delivered once daily for 28 consecutive days, produced a significant improvement in lung function, was well-tolerated, and had a side-effect profile

Emergency Filtration Products’s (EFP) NanoMask is a surgical mask containing a hydrophobic filter medium coated with NanoFense, a proprietary nano silver antimicrobial formulation developed by EFP’s future merger

SuperGen’s SGI-1776 was identified as an orally available, potent and selective inhibitor of the PIM kinases. SGI-1776 was found to induce cell cycle arrest, dose dependent apoptosis and

In this small, randomized, double-blind, Phase II, multicenter, placebo-controlled, exploratory study, researchers investigated whether monotherapy with Orencia, administered for six months and then withdrawn, was more effective than

In the suit, Elan claimed that Abraxis infringed upon two of its patents 5,834,025 and 5,399,363, asserting Abraxane uses technology protected by Elan-owned patents. Elan later withdrew its